>
Neogenomics Inc logo

NEO - Neogenomics Inc Share Price

$44.44 -0.9  -2.1%

Last Trade - 9:00pm

Sector
Healthcare
Size
Large Cap
Market Cap £4.04bn
Enterprise Value £4.01bn
Revenue £354.3m
Position in Universe 1386th / 7242
Bullish
Bearish
Unlock NEO Revenue
Momentum
Relative Strength (%)
1m -8.78%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
99.8 231.8 240.3 276.7 408.8 444.4 498.1 580 +34.8%
+63.9 -90.0
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, NeoGenomics,Inc. revenues increased 23% to $237.3M. Net income totaled$53.8M vs. loss of $13.8M. Revenues reflect Clinicaltesting segment increase of 19% to $197.9M, Pharma Servicessegment increase of 51% to $39.4M. Net Income reflects Losson termination of cash flow hedge decrease from $3.5M(expense) to $0K, Loss on extinguishment of debt decreasefrom $1.4M (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NEO Revenue Unlock NEO Revenue

Net Income

NEO Net Income Unlock NEO Revenue

Normalised EPS

NEO Normalised EPS Unlock NEO Revenue

PE Ratio Range

NEO PE Ratio Range Unlock NEO Revenue

Dividend Yield Range

NEO Dividend Yield Range Unlock NEO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NEO EPS Forecasts Unlock NEO Revenue
Profile Summary

NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The Company' Pharma Services segment provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated October 29, 1998
Public Since December 10, 2012
No. of Shareholders: 665
No. of Employees: 1,700
Sector Healthcare
Industry Healthcare Providers & Services
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Capital Market
Shares in Issue 122,816,314
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NEO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NEO
Upcoming Events for NEO
Thursday 4th November, 2021
Q3 2021 Neogenomics Inc Earnings Release
Thursday 4th November, 2021
Q3 2021 Neogenomics Inc Earnings Call
Tuesday 22nd February, 2022 Estimate
Q4 2021 Neogenomics Inc Earnings Release
Frequently Asked Questions for Neogenomics Inc
What is the Neogenomics Inc share price?

As of 9:00pm, shares in Neogenomics Inc are trading at $44.44, giving the company a market capitalisation of £4.04bn. This share price information is delayed by 15 minutes.

How has the Neogenomics Inc share price performed this year?

Shares in Neogenomics Inc are currently trading at $44.44 and the price has moved by 5.61% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neogenomics Inc price has moved by -18.95% over the past year.

What are the analyst and broker recommendations for Neogenomics Inc?

Of the analysts with advisory recommendations for Neogenomics Inc, there are there are currently 6 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neogenomics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Neogenomics Inc next release its financial results?

Neogenomics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Neogenomics Inc dividend yield?

Neogenomics Inc does not currently pay a dividend.

Does Neogenomics Inc pay a dividend?

Neogenomics Inc does not currently pay a dividend.

When does Neogenomics Inc next pay dividends?

Neogenomics Inc does not currently pay a dividend.

How do I buy Neogenomics Inc shares?

To buy shares in Neogenomics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neogenomics Inc?

Shares in Neogenomics Inc are currently trading at $44.44, giving the company a market capitalisation of £4.04bn.

Where are Neogenomics Inc shares listed? Where are Neogenomics Inc shares listed?

Here are the trading details for Neogenomics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: NEO
What kind of share is Neogenomics Inc?

Based on an overall assessment of its quality, value and momentum, Neogenomics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Neogenomics Inc share price forecast 2021?

Shares in Neogenomics Inc are currently priced at $44.44. At that level they are trading at 24.39% discount to the analyst consensus target price of 0.00.

Analysts covering Neogenomics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.21 for the next financial year.

How can I tell whether the Neogenomics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neogenomics Inc. Over the past six months, the relative strength of its shares against the market has been -15.44%. At the current price of $44.44, shares in Neogenomics Inc are trading at -3.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neogenomics Inc PE Ratio?

The Neogenomics Inc PE ratio based on its reported earnings over the past 12 months is 69.93. The shares are currently trading at $44.44.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Neogenomics Inc?

Neogenomics Inc's management team is headed by:

Douglas VanOort - DRC
George Cardoza - CEX
Kevin Johnson - IND
Bruce Crowther - IND
Lynn Tetrault - NEC
Alison Hannah - IND
Kathryn McKenzie - CFO
William Bonello - CEX
Stephanie Bywater - CCO
Denise Pedulla - GCN
Cynthia Dieter - CAO
Mark Mallon - CEO
Marcus Silva - CMO
Gina Wallar - CEX
Clive Morris - CEX
Who are the major shareholders of Neogenomics Inc?

Here are the top five shareholders of Neogenomics Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 13.76% (16.9m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.93% (12.2m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.66% (8.18m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 4.52% (5.55m shares)
Artisan Partners Limited Partnership Investment Advisor
Percentage owned: 3.94% (4.84m shares)
Similar to NEO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.